Results 1 to 2 of 2
Page 1 of 1
TypeTitleAuthor(s)YearViews
Phase II multi-centre, dose-escalating study of LB80380 (ANA380) in hepatitis B patients with lamivudine-resistant YMDD mutant HBVLai, CL; Han, KH; Yoon, SK; Um, SH; Yuen, MF; Kim, HS; Kim, HR; Chung, HC; Kim, CR; Hsyu, P; Averett, D; Worland, S; Kim, J2006209
 
Phase I/II double-blind, randomized, placebo-controlled study of the novel anti-HBV agent LB80380/ANA380 in patients with chronic HBV infection.Yuen, RMF; Kim, J; Averett, D; Wong, DKH; Kim, CR; Kerr, B; Ngai, WS; Yuen, JCH; Lai, CL2004189
 
Page 1 of 1
Export Records
Step 1: Select content and export format
  • Citation only
Step 2: Select export method
  • Download